Compare POWWP & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POWWP | TGTX |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 7.9B |
| IPO Year | 2018 | 2008 |
| Metric | POWWP | TGTX |
|---|---|---|
| Price | $23.75 | $53.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $49.80 |
| AVG Volume (30 Days) | 6.9K | ★ 1.8M |
| Earning Date | N/A | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 95.61 | ★ 1746.67 |
| EPS | 0.02 | ★ 0.17 |
| Revenue | N/A | ★ $2,785,000.00 |
| Revenue This Year | N/A | $49.08 |
| Revenue Next Year | N/A | $26.69 |
| P/E Ratio | $1,187.50 | ★ $321.47 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.75 | $26.76 |
| 52 Week High | $25.50 | $59.30 |
| Indicator | POWWP | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.62 | 53.83 |
| Support Level | $23.70 | $51.51 |
| Resistance Level | $24.61 | $58.04 |
| Average True Range (ATR) | 0.38 | 2.69 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 59.44 | 57.53 |
Outdoor Holding Co Formerly AMMO Inc is the owner of GunBroker.com, the online marketplace serving the firearms and shooting sports industries, and a vertically integrated producer of high-performance ammunition and components. It engages in the design, manufacture, and market of ammunition products in the Shooting sports industry in the United States. The firm's product segment comprises Ammunition and Marketplace. The Ammunition segment engages in the design, production, and marketing of ammunition and ammunition component products and the marketplace segment consists of the GunBroker.com marketplace. The company generates the majority of its revenue from the Ammunition segment.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.